Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Over 2, phase 3 studies, brexpiprazole-treated patients demonstrated greater response rates across various levels on the Cohen-Mansfield Agitation Index and Clinical Impression Scale-Improvement assessment.

Improvements in Alzheimer Agitation, Response Rates Seen Through Brexpiprazole

Combination of atogepant and ubrogepant resulted in minimal adverse events, and were safe and well-tolerated over a 12-week period.

Concomitant Atogepant and Ubrogepant for Acute and Preventive Migraine Demonstrates Safety

Videos

The executive vice president of research at National MS Society talked about the Dystel Prize which is presented at AAN to a recognized individual who promotes further advancements in understanding and treating MS. [WATCH TIME: 3 minutes]

Recognizing Excellence in Multiple Sclerosis Research, the Dystel Prize: Bruce Bebo, PhD

Results showed consistent reductions in monthly migraine days over 48 weeks, with a favorable safety profile observed.

Long-Term Atogepant Effective, Safe as Migraine Preventive, Open-Label Studies Show

Director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital.

The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]

New Insights into BTK Inhibitors and MRI Techniques for Smoldering MS: Thomas F. Scott, MD

, has been with the team since September 2022. Follow her on Twitter 

The executive vice president and chief research officer of the Muscular Dystrophy Association shared her reaction to the recent FDA approval of givinostat for Duchenne muscular dystrophy.

NeuroVoices: Sharon Hesterlee, PhD, on Givinostat’s Approval for Duchenne Muscular Dystrophy, Future Prospects

Manager of Health Literacy at National MS Society.

Elizabeth Miller, MA, the manager of health literacy at the National MS Society, discussed the impact of health literacy in the multiple sclerosis community. 

Advancing Equity and Inclusion: Health Literacy for the MS Community and Beyond

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

Samuel Hunter, MD, PhD

Articles